ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Biohaven Provides Update on Phase 2/3 Trial, Alzheimer's Program
January 20, 2021Biohaven Pharmaceutical has completed a focused analysis of the topline co-primary and key secondary data from its Phase 2/3 clinical trial of troriluzole as a symptomatic treatment in mild-to-moderate Alzheimer's disease (AD). -
Biohaven Begins Phase 3 Troriluzole Trial for Obsessive-Compulsive Disorder
January 11, 2021Biohaven has commenced enrollment in a Phase 3 clinical trial assessing the efficacy and safety of troriluzole in patients with obsessive-compulsive disorder (OCD). -
Biohaven Announces Issuance of Composition of Matter Patent on Troriluzole by the USPTO
December 11, 2019Biohaven Pharmaceutical announced the U.S. Patent and Trademark Office (USPTO) issued U.S. Pat. No. 10,485,791 on November 26, 2019 relating to troriluzole.
Pharma Sources Insight January 2025
